^
    Back
    Association details:
    Biomarker:FGFR3 mutation
    Cancer:Urothelial Cancer
    Drug:Lytgobi (futibatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of TAS-120 in Patients With Advanced Solid Tumors

    Excerpt:
    ...- Patients with advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations...
    Trial ID:
    FOENIX-CCA2
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

    Published date:
    09/22/2021
    Excerpt:
    Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...FGFR3 mutations (urothelial), and FGFR3 fusions/rearrangements (mostly CNS tumors...FGFR1 mutations (urothelial cancer) also had targetlesion shrinkage...Futibatinib demonstrated activity in urothelial carcinoma (with responses in patients harboring FGFR3 or FGFR1 mutations), showing an ORR of 16% and DCR of 47%...
    DOI:
    10.1158/2159-8290.CD-21-0697
    Trial ID:
    FOENIX-CCA2